EGFR and cancer: These findings suggest that studies of muscle fiber type in patients receiving EGFR inhibitor treatment for cancer would be valuable to determine whether EGFR inhibitors have this effect in humans in vivo, and therefore whether EGFR inhibitors may have therapeutic potential for patients, for example with COPD, with a locomotor muscle ST to FT fiber-type.